TABLE 1.

Demographic and Clinical Characteristics and Outcomes of SOT and HCT Recipients Treated With Foscarnet for Resistant/Refractory CMV

	SOT (n = 22)*	HCT (n = 17)**
M/F	16M, 6F	8M, 9F
Median Age at Transplant	54 (25–68)	33 (8–66)
CMV D+/R−	17	3
CMV D+/R+	4	4
CMV D−/R+	0	3***
CMV D−/R+	0	4
CMV D−/R−	1	0
GCV-Resistant****	13/22 (59%)	2/17 (12%)
Median Peak Viral Load*****	241 500 (765–45,500 000) IU/mL	16 100 (617–469 000) IU/mL
Median Days Post-Transplant When FOS Started	194 (93–542)	73 (29–521)
Tissue-Invasive CMV	7/22 (32%)	4/17 (24%)
Virologic Failure on FOS	6/22 (27%)	7/17 (41%)
Mortality Within 1 Year****	2/22 (9%)	10/17 (59%)
>20% Decrease in eGFR by End of FOS	12/22 (55%)	8/17 (47%)

^*SOT recipients included kidney (13), lung (4), kidney/pancreas (2), liver (2), heart (1).

^**HCT recipients included myeloablative haploidentical donor (4), myeloablative matched related donor (2), myeloablative 5/6 antigen related donor (1), myeloablative matched unrelated donor (1), nonmyeloablative haploidentical donor (6), nonmyeloablative matched related donor (1), nonmyeloablative matched unrelated donor (1), double cord transplant (1). Underlying diagnoses included acute myelogenous leukemia (8), chronic myelomonocytic leukemia/acute myelogenous leukemia (1), acute lymphoblastic leukemia (1), mixed lineage leukemia (1), dyskeratosis congenita with myelodysplastic syndrome (2), myelodysplastic syndrome (1), sickle cell disease (1), Hodgkin disease (1), and nonHodgkin’s lymphoma (1).

^***Four patients (all HCT) had missing donor information; 3 of these were R+ (CMV D−/R+)and 1 had missing recipient information also.

^****p = 0.003 for % ganciclovir-resistant in SOT vs HCT, and p = 0.001 for % mortality in SOT vs HCT; other results were not statistically significant.

^*****Units of viral load were DNA copies/mL before 4/2013 and IU/mL from 4/2013 onward: viral loads before 4/2013 were converted to IU/mL using a conversion factor of 0.9.